|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||46.01 / 60.45|
What do you get from participation with the president, if the president doesn't represent the country's values?
Despite a Phase 3 stumble, BMY stock is holding up.
Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
Late stage trials failed to show significant statistical efficacy.
Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and...
Move over, Helene, I'm getting in on what appears to be a breakout.
Bristol-Myers Squibb Company (NYSE:BMY) and IFM Therapeutics (IFM) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital...
One of the hottest biotech stocks of the last month is selling off.
Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.
I've heard all of the bearish arguments, but I don't believe them.
A glimpse of what to expect during Tuesday's pre-market.
Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.
Several stocks spent Monday's trading session in the red, and here's why.
Bristol-Myers Squibb Company (NYSE:BMY) and Clovis Oncology, Inc.
The results from a clinical trial of AstraZeneca's lung cancer treatment increase uncertainty about Bristol-Myers' immuno-oncology franchise, according to BMO analyst Alex Arfaei.
Shares lost more than 16% in London trading
The Nasdaq tumbles and the S&P 500 slides. The Dow rises slightly.
U.S. stock futures point higher after Facebook shares jump.
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2017 which were highlighted by strong sales for key products Opdivo and Eliquis and regulatory approvals for Opdivo, the...
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission (EC) has approved ORENCIA alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis (PsA) in adult...
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.